Related Experiment Video

Updated: Mar 16, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment

Jan-Erik Karlsson1, Walid El-Saadi2, Mustafa Ali3

  • 1Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping SE-551 85, Sweden Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden jan-erik.karlsson@lj.se.

European Heart Journal. Cardiovascular Pharmacotherapy
|August 18, 2016
PubMed
Abstract

Insights

Mangafodipir (MnDPDP) shows potential as a cardioprotective agent during ST-segment elevation myocardial infarction (STEMI) treatment. This study found it safe and observed a significant reduction in left ventricular thrombi, suggesting benefits for reperfusion therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Oxidative stress plays a critical role in myocardial ischemia-reperfusion injury.
  • Mitochondrial dysfunction contributes to the pathophysiology of ST-segment elevation myocardial infarction (STEMI).
  • Mangafodipir (MnDPDP) is a catalytic antioxidant with superoxide dismutase mimetic and iron chelating properties.

Purpose of the Study:

  • To evaluate the feasibility and safety of mangafodipir (MnDPDP) as a cardioprotective adjunct in primary percutaneous coronary intervention (pPCI) for STEMI patients.
  • To assess the impact of MnDPDP on myocardial injury biomarkers, infarct size, and left ventricular function.
  • To investigate the effect of MnDPDP on the incidence of left ventricular thrombi post-STEMI.

Main Methods:

  • A randomized controlled trial comparing MnDPDP (n=10) with saline placebo (n=10) in STEMI patients undergoing pPCI.
  • MnDPDP administered as a brief intravenous infusion before balloon inflation.
  • Assessment of ST-segment resolution, plasma biomarkers, cardiac magnetic resonance imaging for infarct size and ejection fraction, and echocardiography for left ventricular thrombi.

Main Results:

  • MnDPDP was well-tolerated, with no significant impact on heart rate or blood pressure.
  • Despite longer ischemic times in the MnDPDP group, plasma biomarker releases were similar between groups.
  • A trend towards improved ST-segment resolution and a significant reduction in left ventricular thrombi (1 of 10 vs. 5 of 8) were observed with MnDPDP.

Conclusions:

  • Mangafodipir (MnDPDP) is a safe adjunct therapy for reperfusion in STEMI.
  • The observed reduction in left ventricular thrombi suggests a potential cardioprotective benefit.
  • Further investigation in larger Phase II trials is warranted to confirm the efficacy of MnDPDP.
Keywords:
Cardiac reperfusion injuryMitochondrial superoxide dismutaseOxidative stressPrimary PCISTEMISmall molecular catalytic antioxidants

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
386
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
299
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
465
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
501
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716